Article 433: Clinical Trials Transparency Efforts Multiply

• Thomson CenterWatch has been tracking the progress of pharmaceutical companies’ compliance with expanding requirements for clinical trials transparency over the past 18 months. With the crucial International Committee of Medical Journal Editors’ deadline passed in September, CenterWatch reviews pharma’s drive to comply with it and a number of government and industry-sponsored initiatives.

Article 434: Advocacy Groups Lead in Diversity

• In spite of a growing need for trial subjects, sponsor companies’ tools and techniques for increasing diversity remain inconsistent, unsophisticated and underdeveloped.

Article 435: Post-Directive Pharmacovigilance Woes

• Problems with implementation of EMEA's EudraVigilance database continue to hinder the goal of Directive2001/20EC's requirement to create a pool of analysis-friendly data to spot dangers within trials earlier.

Article 436: Eye on: Obesity

• Obesity affects more than 20% of adults in developed countries. CenterWatch has identified a pipeline of 17 drugs in development for obesity.